390900

4-Hydroxyphenylretinamide

A synthetic amide of all-trans retinoic acid (RA) that displays reduced toxicity relative to RA while maintaining significant biological activity.

• Sinónimos: 4-Hydroxyphenylretinamide, Fenretinide, 4HPR, N-(4-Hydroxyphenyl)-all- trans Retinamide
• Fórmula empírica (notación de Hill): C₂₆H₃₃NO₂
• Número CAS: 65646-68-6
• Peso molecular: 391.55
• UNSPSC Code: 12352200
• NACRES: NA.77
• MDL number: MFCD00792674
• Assay: ≥97% (TLC)
• Form: solid
• Storage condition: OK to freeze, protect from light

Propiedades

• Quality Segment: 100
• description: Merck USA index - 14, 3998
• assay: ≥97% (TLC)
• form: solid
• manufacturer/tradename: Calbiochem^®
• storage condition: OK to freeze, protect from light
• color: orange
• solubility: DMSO: 25 mg/mL, acetone: soluble, ethanol: soluble
• shipped in: ambient
• storage temp.: −20°C
• SMILES string: N(c2ccc(cc2)O)C(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(CCCC1(C)C)C
• InChI: 1S/C26H33NO2/c1-19(11-16-24-21(3)10-7-17-26(24,4)5)8-6-9-20(2)18-25(29)27-22-12-14-23(28)15-13-22/h6,8-9,11-16,18,28H,7,10,17H2,1-5H3,(H,27,29)/b9-6+,16-11+,19-8+,20-18+
• InChI key: AKJHMTWEGVYYSE-FXILSDISSA-N

Descripción

General description

A synthetic amide of all-trans retinoic acid (RA) that displays reduced toxicity relative to RA while maintaining significant biological activity. Active in the prevention and treatment of a variety of neoplasms in animals. Inhibits proliferation in cell lines of human breast cancer, prostate adenocarcinoma, and ovarian carcinoma. Inhibits angiogenesis, as well as endothelial cell motility and tubule formation. Induces apoptosis in malignant hemopoietic cell lines.

Biochem/physiol Actions

Cell permeable: no

Primary Target
Active in the prevention and treatment of a variety of neoplasms in animals.

Product does not compete with ATP.

Reversible: no

Packaging

Packaged under inert gas

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Formelli, F., et al. 1996. FASEB J. 10, 1014.
Naik, H.R., et al. 1995. Adv. Pharmacol. 33, 315.
Delia, D., et al. 1993. Cancer Res. 53, 6036.
Pienta, K.J., et al. 1993. Cancer Res. 53, 224.
Grubbs, C.J., et al. 1990. Anticancer Res. 10, 661.
McCarthy, D.J., et al. 1987. Cancer Res.47, 5014.
Moon, R.C., et al. 1979. Cancer Res.39, 1339.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Harmful & Carcinogenic / Teratogenic (E)

Información de seguridad

• pictograms: GHS08,GHS07
• signalword: Danger
• hcodes: H302 + H312 + H332,H315,H319,H335,H360
• pcodes: P280 - P301 + P312 - P302 + P352 + P312 - P304 + P340 + P312 - P305 + P351 + P338 - P308 + P313
• Hazard Classifications: Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Repr. 1B - Skin Irrit. 2 - STOT SE 3
• target_organs: Respiratory system
• Clase de almacenamiento: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable